VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2022 | SEQUENCE: nab-paclitaxel/gemcitabine with modified FOLFOX in pancreatic cancer

Whilst nab-paclitaxel and gemcitabine are prescribed for patients with basal subtype of metastatic pancreatic cancer, FOLFIRINOX is the standard of care for patients with the classic subtype. Alfredo Carrato, MD, PhD, Hospital Ramón y Cajal, Madrid, Spain, discusses findings from the phase I SEQUENCE trial (NCT02504333) of nab-paclitaxel and gemcitabine followed by modified FOLFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Patients received the investigatory regimen over a six week period as first line treatment and a superior median overall survival (OS) rate was reported in receiving the novel combination. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter